Abbott's sibutramine pulled in Italy

18 March 2002

Abbott Laboratories' obesity drug sibutramine has been temporarilywithdrawn from the market in Italy, where it is sold as Reductil (by Abbott), Ectiva (by Bracco) and Reduxade (by GlaxoSmithKline), on safety concerns. The move follows one death and a number of other adverse reactions in patients taking sibutramine, and a Ministry of Health re-assessment of the drug's risk/benefit ratio is now ongoing.

Abbott said that sibutramine is registered in more than 70 countries, adding that it has continued to routinely monitor its safety profile and provide semi-annual safety updates to regulatory authorities throughout Europe. "Based on these reports, there has been no substantial change to the risk/benefit profile of the drug," said the firm in a statement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight